Athersys (ATHX) Receiving Favorable News Coverage, Report Shows

News headlines about Athersys (NASDAQ:ATHX) have been trending positive on Saturday, Alpha One Sentiment Analysis reports. The research group, a division of Accern, identifies negative and positive news coverage by reviewing more than twenty million news and blog sources in real time. Alpha One ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Athersys earned a media sentiment score of 0.47 on Alpha One’s scale. Alpha One also gave news articles about the biopharmaceutical company an impact score of 22 out of 100, meaning that recent news coverage is very unlikely to have an effect on the stock’s share price in the next few days.

Here are some of the news articles that may have effected Alpha One Sentiment’s rankings:

Shares of Athersys (NASDAQ:ATHX) traded up 2.78% on Friday, hitting $1.48. 788,561 shares of the stock were exchanged. The company has a 50-day moving average price of $1.50 and a 200-day moving average price of $1.44. Athersys has a one year low of $1.02 and a one year high of $2.60. The firm’s market capitalization is $164.75 million.

Athersys (NASDAQ:ATHX) last posted its earnings results on Tuesday, May 9th. The biopharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.07) by $0.01. The company had revenue of $1.50 million during the quarter, compared to analysts’ expectations of $0.45 million. Athersys had a negative net margin of 17.12% and a negative return on equity of 22.82%. Athersys’s quarterly revenue was down 90.3% compared to the same quarter last year. During the same quarter last year, the company posted $0.06 EPS. Equities research analysts expect that Athersys will post ($0.26) earnings per share for the current year.

ATHX has been the subject of a number of research analyst reports. William Blair reissued an “outperform” rating on shares of Athersys in a research report on Tuesday, March 28th. Maxim Group set a $9.00 target price on shares of Athersys and gave the stock a “buy” rating in a research report on Monday, March 20th. Needham & Company LLC initiated coverage on shares of Athersys in a research report on Tuesday, February 7th. They set a “buy” rating and a $7.00 target price for the company. Finally, Zacks Investment Research lowered shares of Athersys from a “buy” rating to a “hold” rating in a research report on Tuesday, May 9th. Two equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of $5.75.

COPYRIGHT VIOLATION WARNING: “Athersys (ATHX) Receiving Favorable News Coverage, Report Shows” was originally published by Markets Daily and is the sole property of of Markets Daily. If you are accessing this news story on another domain, it was illegally stolen and reposted in violation of U.S. and international trademark and copyright law. The original version of this news story can be read at https://www.themarketsdaily.com/2017/05/20/athersys-athx-receiving-favorable-news-coverage-report-shows.html.

About Athersys

Athersys, Inc is an international biotechnology company that is focused primarily in the field of regenerative medicine. The Company’s MultiStem cell therapy, an allogeneic stem cell product, is its lead platform product and is in later-stage clinical development. Its clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the standard of care is limited or inadequate for many patients.

12 Month Chart for NASDAQ:ATHX

Receive News & Ratings for Athersys Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athersys Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply